Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Research & Development: 2017-2024

Historic Research & Development for Tonix Pharmaceuticals Holding (TNXP) over the last 8 years, with Dec 2024 value amounting to $40.0 million.

  • Tonix Pharmaceuticals Holding's Research & Development rose 1.92% to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.8 million, marking a year-over-year decrease of 26.55%. This contributed to the annual value of $40.0 million for FY2024, which is 53.87% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Research & Development of $40.0 million as of FY2024, which was down 53.87% from $86.7 million recorded in FY2023.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Research & Development ranged from a high of $86.7 million in FY2023 and a low of $36.2 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $81.9 million (2022), whereas its average is $69.5 million.
  • In the last 5 years, Tonix Pharmaceuticals Holding's Research & Development skyrocketed by 98.75% in 2020 and then slumped by 53.87% in 2024.
  • Over the past 5 years, Tonix Pharmaceuticals Holding's Research & Development (Yearly) stood at $36.2 million in 2020, then surged by 90.39% to $68.8 million in 2021, then grew by 18.94% to $81.9 million in 2022, then climbed by 5.84% to $86.7 million in 2023, then tumbled by 53.87% to $40.0 million in 2024.